Literature DB >> 32428553

CXCR4/MIF axis amplifies tumor growth and epithelial-mesenchymal interaction in non-small cell lung cancer.

Benedikt Jäger1, Denise Klatt2, Linda Plappert3, Heiko Golpon4, Stefan Lienenklaus5, Philippe Dänzer Barbosa2, Axel Schambach6, Antje Prasse7.   

Abstract

Overexpression of C-X-C chemokine receptor type 4 (CXCR4) has been shown in several cancers, including non-small cell lung cancer (NSCLC) and is linked to early metastasis and worse prognosis. The crosstalk between cancer cells and tumor stroma promotes the growth and metastasis and CXCR4 signaling is a key element of this crosstalk. To test the effects of CXCR4 overexpression (CXCR4-OE), we transduced the human NSCLC cell line A549 by using a lentiviral vector. A 3D cell culture model showed generations of tumorspheres and the effects derived by the co-culturing of lung fibroblasts. Using a xenograft mouse model, we also studied the effects of CXCR4-OE in pulmonary cell engraftment and tumor burden in vivo. Our data indicate that CXCR4-OE leads to increased tumorsphere formation and epithelial-mesenchymal transition (EMT). CXCR4-OE by A549 cells resulted in a significant increase in the production of the CXCR4-ligand macrophage migration inhibitory factor (MIF) compared to those transduced with an empty vector (EV) or in which the CXCR4 expression was deleted (KO). In our in vitro system, we did not detect any production of the canonical CXCR4 ligand CXCL12. Autocrine MIF production and CXCR4 signaling are part of a self-perpetuating loop that amplifies tumor growth and EMT. Co-culture with lung fibroblasts further increased tumorsphere formation, partially driven by an increase in IL-6 production. When A549 cells were injected into murine lungs, we observed more abundant and significantly larger tumor lesions in recipients of CXCR4-OE A549 cells compared to those receiving EV or KO cells, consistent with our in vitro findings. Treatment of mice with the MIF antagonist ISO-1 resulted in significantly less tumor burden. In conclusion, our data highlight the role of the CXCR4-OE/MIF/IL-6 axis in epithelial mesenchymal crosstalk and NSCLC progression.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  CXCR4; Cancer; Epithelial mesenchymal crosstalk; MIF; NSCLC

Year:  2020        PMID: 32428553     DOI: 10.1016/j.cellsig.2020.109672

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  11 in total

1.  MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment.

Authors:  Laura Garcia-Gerique; Marta García; Alícia Garrido-Garcia; Soledad Gómez-González; Montserrat Torrebadell; Estela Prada; Guillem Pascual-Pasto; Oscar Muñoz; Sara Perez-Jaume; Isadora Lemos; Noelia Salvador; Monica Vila-Ubach; Ana Doncel-Requena; Mariona Suñol; Angel M Carcaboso; Jaume Mora; Cinzia Lavarino
Journal:  BMC Cancer       Date:  2022-06-17       Impact factor: 4.638

2.  The Relationship Between Cancer and Functional and Structural Markers of Subclinical Atherosclerosis: A Systematic Review and Meta-Analysis.

Authors:  Yuhong Diao; Zhixing Liu; Li Chen; Weiping Zhang; Dandan Sun
Journal:  Front Cardiovasc Med       Date:  2022-05-04

3.  Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.

Authors:  Chengde Wu; Xiang Rao; Wei Lin
Journal:  Cancer Med       Date:  2020-12-12       Impact factor: 4.452

4.  Ceruloplasmin overexpression is associated with oncogenic pathways and poorer survival rates in clear-cell renal cell carcinoma.

Authors:  Yong Zhang; Zhan Chen; Jian-Gang Chen; Xin-Feng Chen; Dong-Hua Gu; Zhen-Min Liu; Ya-Dong Gao; Bing Zheng
Journal:  FEBS Open Bio       Date:  2021-09-28       Impact factor: 2.693

5.  Functional Tumor Targeting Nano-Systems for Reprogramming Circulating Tumor Cells with In Situ Evaluation on Therapeutic Efficiency at the Single-Cell Level.

Authors:  Xiao-He Ren; Xiao-Yan He; Chang Xu; Di Han; Si-Xue Cheng
Journal:  Adv Sci (Weinh)       Date:  2022-05-20       Impact factor: 17.521

6.  Disease-related blood-based differential methylation in cystic fibrosis and its representation in lung cancer revealed a regulatory locus in PKP3 in lung epithelial cells.

Authors:  Esther Schamschula; Angelika Lahnsteiner; Yassen Assenov; Wolfgang Hagmann; Nadja Zaborsky; Markus Wiederstein; Anna Strobl; Frauke Stanke; Thomas Muley; Christoph Plass; Burkhard Tümmler; Angela Risch
Journal:  Epigenetics       Date:  2021-08-20       Impact factor: 4.861

7.  MIF promoter polymorphism increases peripheral blood expression levels, contributing to increased susceptibility and poor prognosis in hepatocellular carcinoma.

Authors:  Lifeng Qin; Jinmei Qin; Xiaoping Lv; Caiqiao Yin; Qian'e Zhang; Jiqiao Zhang
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

8.  Epigenetic Silencing of LMX1A Contributes to Cancer Progression in Lung Cancer Cells.

Authors:  Ti-Hui Wu; Shan-Yueh Chang; Yu-Lueng Shih; Chih-Feng Chian; Hung Chang; Ya-Wen Lin
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

9.  Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione Derivative Inhibits d-Dopachrome Tautomerase Activity and Suppresses the Proliferation of Non-Small Cell Lung Cancer Cells.

Authors:  Zhangping Xiao; Angelina Osipyan; Shanshan Song; Deng Chen; Reinder A Schut; Ronald van Merkerk; Petra E van der Wouden; Robbert H Cool; Wim J Quax; Barbro N Melgert; Gerrit J Poelarends; Frank J Dekker
Journal:  J Med Chem       Date:  2022-01-18       Impact factor: 7.446

10.  CXCL12/CXCR4 facilitates perineural invasion via induction of the Twist/S100A4 axis in salivary adenoid cystic carcinoma.

Authors:  Mei Zhang; Min Zheng; Li Dai; Wei-Long Zhang; Hua-Yang Fan; Xiang-Hua Yu; Xin Pang; Peng Liao; Bing-Jun Chen; Sha-Sha Wang; Ming-Xin Cao; Xiang-Rui Ma; Xin-Hua Liang; Ya-Ling Tang
Journal:  J Cell Mol Med       Date:  2021-06-25       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.